Search

Fengtian F Xue

from Potomac, MD
Age ~48
Get Report
Also known as:
Feng Tian Xue, Feng T Xue, Tian Xue Feng, Xue Fengtian, Xue Feng
Related to:
Xiyou Chen, 61Xue Feng
Connected to:
Amy C Xue, 36Cathleen S Xue, 49Chenming Xue, 42Cherry Y Xue, 43Cindy Z Xue, 79Emily Xue, 35Feifei S Xue, 40Gang Xue, 70Jenny G Xue, 76Jian F Xue, 44

Fengtian Xue Phones & Addresses

  • Potomac, MD
  • Baltimore, MD
  • Baton Rouge, LA
  • Providence, RI
  • Pawtucket, RI

Work

Company: University of louisiana at lafayette May 2009 Position: Assistant professor

Education

Degree: Ph.D. School / High School: Brown University 2001 to 2007 Specialities: Chemistry

Skills

Chemistry • Medicinal Chemistry

Industries

Higher Education

Resumes

Resumes

Fengtian Xue Photo 1

Assistant Professor

View page
Location:
11900 Piney Glen Ln, Potomac, MD 20854
Industry:
Higher Education
Work:
University of Louisiana at Lafayette since May 2009
Assistant Professor
Northwestern University May 2007 - May 2009
Postdoc
Education:
Brown University 2001 - 2007
Ph.D., Chemistry University of Science and Technology of China 1996 - 2001
BS, Chemistry
Skills:
Chemistry
Medicinal Chemistry

Publications

Us Patents

Potent And Selective Neuronal Nitric Oxide Synthase Inhibitors With Improved Membrane Permeability

View page
US Patent:
8299100, Oct 30, 2012
Filed:
Jan 25, 2010
Appl. No.:
12/693196
Inventors:
Richard B. Silverman - Northbrook IL, US
Fengtian Xue - Baton Rouge LA, US
Assignee:
Northwestern University - Evanston IL
International Classification:
A61K 31/4439
C07D 401/06
US Classification:
514343, 5462784
Abstract:
Compounds and related compositions and methods as can be used to inhibit neuronal nitric oxide synthase and can be employed in the treatment of various neurodegenerative diseases, such compounds of a formula.

Aminopyridine Dimer Compounds, Compositions And Related Methods For Neuronal Nitric Oxide Synthase Inhibition

View page
US Patent:
8278084, Oct 2, 2012
Filed:
Feb 11, 2010
Appl. No.:
12/704205
Inventors:
Richard B. Silverman - Northbrook IL, US
Fengtian Xue - Baton Rouge LA, US
Assignee:
Northwestern University - Evanston IL
International Classification:
C07D 401/14
C07D 401/10
C12N 9/99
US Classification:
435184, 546184, 546264, 546256
Abstract:
Nitric oxide synthase (NOS) inhibitor compounds comprising bi-terminal aromatic ring moieties, and related methods of NOS inhibition.

Chiral Pyrrolidine Core Compounds En Route To Inhibitors Of Nitric Oxide Synthase

View page
US Patent:
8389731, Mar 5, 2013
Filed:
May 17, 2010
Appl. No.:
12/781139
Inventors:
Richard B. Silverman - Northbrook IL, US
Fengtian Xue - Baton Rouge LA, US
Assignee:
Northwestern University - Evanston IL
International Classification:
C07D 401/00
US Classification:
5462764
Abstract:
Diastereomeric pyrrolidine compounds and methods of preparation, as can be used en route to the preparation of a range of nitric oxide synthase inhibitors.

Inhibitors Of Nitric Oxide Synthase For Treatment Of Melanoma

View page
US Patent:
8642282, Feb 4, 2014
Filed:
Jan 12, 2012
Appl. No.:
13/348819
Inventors:
Richard B. Silverman - Northbrook IL, US
Sun Yang - Foothill Ranch CA, US
Haitao Ji - Salt Lake City UT, US
Fengtian Xue - Baton Rouge LA, US
Thomas L. Poulos - Irvine CA, US
Assignee:
Northwestern University - Evanston IL
The Regents of the University of California - Oakland CA
International Classification:
C12Q 1/34
US Classification:
435 18, 435184
Abstract:
Methods for melanoma treatment and prevention with selective nitric oxide synthase inhibitor compounds and related pharmaceutical compositions, alone or in conjunction with one or more other melanoma therapies.

Chiral Synthesis Of Pyrrolidine Core Compounds En Route To Neuronal Nitric Oxide Synthase Inhibitors

View page
US Patent:
20120004415, Jan 5, 2012
Filed:
Jul 1, 2011
Appl. No.:
13/174982
Inventors:
Richard B. Silverman - Northbrook IL, US
Fengtian Xue - Baton Rouge LA, US
International Classification:
C07D 401/06
C07D 401/14
US Classification:
546256, 5462784
Abstract:
A chiral synthesis of pyrrolidine compounds en route to selective neuronal nitric oxide synthase inhibitors, and representative inhibitor compounds heretofore unattainable.

Intramolecular Hydrogen-Bonded Nitric Oxide Synthase Inhibitors

View page
US Patent:
20120088798, Apr 12, 2012
Filed:
Sep 30, 2011
Appl. No.:
13/250554
Inventors:
Richard B. Silverman - Northbrook IL, US
Fengtian Xue - Baton Rouge LA, US
International Classification:
A61K 31/4439
A61P 25/00
C12N 9/99
C07D 405/14
C07D 401/06
C12N 9/02
US Classification:
514343, 5462784, 435189, 435184
Abstract:
Compounds and related compositions and methods as can be used to selectively inhibit neuronal nitric oxide synthase and as can be employed in the treatment of various neurodegenerative diseases.

Aminopyridine Dimer Compounds, Compositions And Related Methods For Neuronal Nitric Oxide Synthase Inhibition

View page
US Patent:
20130040359, Feb 14, 2013
Filed:
Oct 1, 2012
Appl. No.:
13/573654
Inventors:
Northwestern University - Evanston IL, US
Fengtian Xue - Baton Rouge LA, US
He Huang - Chicago IL, US
Assignee:
Northwestern University - Evanston IL
International Classification:
C07D 401/12
C07D 401/10
C12N 9/99
C07D 401/14
US Classification:
435184, 546264, 546256, 544364
Abstract:
Nitric oxide synthase (NOS) inhibitor compounds comprising bi-terminal aromatic ring moieties, and related methods of NOS inhibition.

Car Activator Agents For Cyclophosphamide-Based Treatments Of Cancer

View page
US Patent:
20200352915, Nov 12, 2020
Filed:
Jun 19, 2018
Appl. No.:
16/623453
Inventors:
- Baltimore MD, US
Fengtian XUE - Potomac MD, US
Dongdong LIANG - Baltimore MD, US
International Classification:
A61K 31/429
C07D 513/04
C07D 498/04
C07D 487/04
A61K 31/424
A61K 31/519
A61P 35/00
A61K 31/704
A61K 31/475
A61K 31/573
Abstract:
The invention relates to selective small molecule human constitutive androstane receptor (hCAR) activators of Formula (I) or (II), pharmaceutical compositions thereof, and use thereof for the treatment of hematologic malignancies and other cancers. The small molecule hCAR activator in combination with CPA based chemotherapy regimen provides a synergistic effect to help promote cytoxicity of the cyclophosphamide (CPA) based anticancer treatments including CHOP regimen (CPA, doxorubicin, vincristine, and prednisone) by preferential induction of CYP2B6 over CYP3A4 and promoting the formation of therapeutically active CPA metabolite 4-OH-CPA.
Control profile
Fengtian F Xue from Potomac, MD, age ~48 Get Report